ClinicalTrials.gg
Not yet recruitingNCT07946666Updated Nov 18, 2026

A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.

An interventional study of Synbiotic Dual Cap® Intervention in Gastrointestinal Discomfort, Nausea and Bloating, sponsored by Epetome. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Epetome · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 292 studies in Nausea with a site in United States — 31 open to participants now, 34 under way, 8 of them phase 3. Nausea · United States.

Planned enrollment
172nd of 262
40 · median 86
Started
2026
with 8 others
No phase
103 of 292
13 open now
Primary completion
2027-02
later than 12 of 33 live
Registered
291st of 292
by date

Among the 292 studies in Nausea with a site in United States, this one is the 172nd largest by planned enrollment of the 262 interventional ones that give a count, is one of 9 that started in 2026, is one of 103 with no phase, reaches primary completion later than 12 of the 33 other live ones, and was the 291st registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

31 of the 292 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Nausea studies recruiting now, 22 (42%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 292 studies in Nausea with a site in United States, or all of them as a file.
02

Study summary

This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.

Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.

03

Conditions studied

  • Gastrointestinal Discomfort
  • Nausea
  • Bloating
  • Constipation
  • Diarrhea
  • GLP-1 Receptor Agonist Therapy-Associated Gastrointestinal Symptoms
  • Obesity
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years.
  • Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
  • Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
  • Currently on a stable GLP-1 dose as directed by their prescribing physician.
  • Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to provide prior to enrollment.
  • In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
  • Reside in the United States.

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
  • Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
  • Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
  • Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
  • Anyone currently participating or planning to participate in another research study during the study period.
  • Currently receiving therapy of any kind.
  • Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
  • Reside in Hawaii.
  • Known allergy or to any ingredient in the Synbiotic Dual Cap®.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Synbiotic Dual Cap® Arm

    Dietary Supplement: Synbiotic Dual Cap® Intervention

Interventions

  • Dietary supplementSynbiotic Dual Cap® Intervention

    Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.

06

What researchers measure

Primary outcomes

  1. Change in Overall Gastrointestinal Comfort

    Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

  2. Change in Bowel Regularity

    Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

  3. Change in Bloating

    Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

  4. Change in Constipation

    Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

  5. Change in Diarrhea

    Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

  6. Change in Nausea

    Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

  7. Change in Post-Meal Fullness Comfort

    Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Participant Perception of Effect on Overall Gastrointestinal Comfort

    Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

  2. Participant Perception of Effect on Bowel Regularity

    Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

  3. Participant Perception of Effect on Bloating

    Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

  4. Participant Perception of Effect on Constipation

    Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

  5. Participant Perception of Effect on Diarrhea

    Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

  6. Participant Perception of Effect on Nausea

    Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

  7. Participant Perception of Effect on Post-Meal Fullness Comfort

    Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires

    Time frame: Week 4, Week 8, and Week 12

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 126 interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946666
Lead sponsor
Epetome
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Dimitra Diamantopoulou
Contact
dimitra@epetome.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion